Therapeutic and adverse actions of serotonin transporter substrates (Q34142899)

31 July 2017

1 reference

title

Therapeutic and adverse actions of serotonin transporter substrates (English)

1 reference

31 July 2017

0 references

Richard B Rothman

1

1 reference

PubMed ID

12163129

31 July 2017

Michael H Baumann

series ordinal

2

1 reference

31 July 2017

1 July 2002

1 reference

Pharmacology & Therapeutics

31 July 2017

1 reference

31 July 2017

95

1 reference

31 July 2017

1

1 reference

31 July 2017

73-88

1 reference

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Neurotransmitter transporters: recent progress

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Neurotransmitter transporters as molecular targets for addictive drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Haemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

TFMPP and RU24969 enhance serotonin release from rat hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Cardiovascular safety of second-generation antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

1-(m-chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Dissociation of serotonergic regulation of anxiety and ethanol self-administration: a study with mCPP

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Agony and ecstasy: a review of MDMA effects and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Craving for cocaine in addicted users. Role of serotonergic mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Cloning and expression of the mouse serotonin transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Quantitation of dexfenfluramine/d-norfenfluramine concentration in primate brain using 19F NMR spectroscopy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Obesity drugs and the heart

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Characterization of d-fenfluramine-induced hypothermia: evidence for multiple sites of action

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Non-linear pharmacokinetics of MDMA ('ecstasy') in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effects of serotonin 5-HT(1) and 5-HT(2) receptor agonists in a conditioned taste aversion paradigm in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Multiple serotonin receptors: opportunities for new treatments for obesity?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Aminorex to fen/phen: an epidemic foretold

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Stereochemistry of the metabolism of MDMA to MDA.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Structure-activity relationships among the halogenated amphetamines

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Reversible and irreversible phases of serotonin depletion by 4-chloroamphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Biological actions of drugs affecting serotonin and eating

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

8-OH-DPAT attenuates the dexfenfluramine-induced increase in extracellular serotonin: an in vivo dialysis study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Differential effects of monoaminergic agonists on alcohol intake in rats fed a tryptophan-enhanced diet.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effects of phentermine and fenfluramine on alcohol consumption and alcohol withdrawal seizures in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Neuroendocrine effects of d-fenfluramine and bromocriptine following repeated smoked cocaine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

A comparison of sibutramine and dexfenfluramine in the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

The human serotonin transporter gene polymorphism-basic research and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Increased plasma serotonin in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Influence of 5-HT3 receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Novel in vivo electrophysiological assay for the effects of cocaine and putative "cocaine antagonists" on dopamine transporter activity of substantia nigra and ventral tegmental area dopamine neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

The effects of drugs used to treat obesity on the autonomic nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Combined serotonin and dopamine indirect agonists correct alcohol craving and alcohol-associated neuroses.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Efflux studies allow further characterisation of the noradrenaline and 5-hydroxytryptamine transporters in rat lungs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

D-, L- and DL-fenfluramine cause long-lasting depletions of serotonin in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Apomorphine does not alter amphetamine-induced dopamine release measured in striatal dialysates

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Ethanol consumption following acute fenfluramine, fluoxetine, and dietary tryptophan

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Allometric issues in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

The Effect of Selective Serotonin Releasing Agents in the Chronic Mild Stress Model of Depression in Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Simultaneous effects of p-chloroamphetamine, d-fenfluramine, and reserpine on free and stored 5-hydroxytryptamine in brain and blood

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Somatodendritic alpha2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotoninergic neuronal systems of non-human primates. A comparison with the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Anorectic drugs and pulmonary hypertension from the bedside to the bench

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Novel synergistic treatment of ethanol withdrawal seizures in rats with dopamine and serotonin agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Neurotoxicity of MDMA and related compounds: anatomic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Serotonin-releasing effects of substituted piperazines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

SSRI treatment decreases prolactin and hyperthermic responses to mCPP.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effects of chronic fenfluramine on blood serotonin, cerebrospinal fluid metabolites, and behavior in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Pharmacologic induction of weight loss to treat type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Suppression of eating by fenfluramine in patients with bulimia nervosa.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Treatment of alcohol and cocaine addiction by the combination of pemoline and fenfluramine: a preliminary case series.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Antiobesity pharmacotherapy in the management of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Guanfacine in essential hypertension: effect on blood pressure, plasma noradrenaline concentration and plasma renin activity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Electrophysiological effects of fluoxetine and duloxetine in the dorsal raphe nucleus and hippocampus.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Immunohistochemical study of short- and long-term effects of DL-fenfluramine on the serotonergic innervation of the rat hippocampal formation.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Serotonin: it's possible to have too much of a good thing

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Effects of fenfluramine on eight outpatients with the syndrome of autism.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Reduced satiating effect of d -fenfluramine in serotonin 5-HT 2C receptor mutant mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Further studies to examine the nature of dexfenfluramine-induced suppression of heroin self-administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

A comparison of the acute effects of dextroamphetamine and fenfluramine in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Drug treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Appetite suppressants and valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

The Effects of Dexfenfluramine on Blood Glucose Control in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

An investigation into the effects of 5-HT agonists and receptor antagonists on ethanol self-administration in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Oxidation of serotonin by superoxide radical: implications to neurodegenerative brain disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Amphetamine and fenfluramine suppress ethanol intake in ethanol-dependent rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

The effects of aminorex and related compounds on brain monoamines and metabolites in CBA mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900234-6

7 January 2021

10.1016/S0163-7258(02)00234-6

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

12163129